Food And Drug Administration Approves Brand New Libido-Boosting Drug for Premenopausal Females

Food And Drug Administration Approves Brand New Libido-Boosting Drug for Premenopausal Females

The united states Food and Drug management (Food And Drug Administration) today approved bremelanotide (Vyleesi, AMAG Pharmaceuticals), a first-in-class melanocortin 4 receptor agonist for hypoactive sexual interest disorder (HSDD) in premenopausal ladies.

It joins flibanserin (Addyi, Sprout Pharmaceuticals), truly the indian women for marriage only other FDA-approved HSDD treatment plan for premenopausal ladies.

The Food And Drug Administration had until 23 to complete the review of bremelanotide’s new drug application (NDA) under the Prescription Drug User Fee Act (PDUFA) june. Read More